NCT06646016 2025-12-26
EPIC
Therakos LLC
Phase 2 Withdrawn
Clinical Trials
28 trialsNCT06508827 2025-07-09
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Indiana University
Phase 2 Withdrawn
NCT03448666 2024-09-23
ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
European Institute of Oncology
Phase 2 Withdrawn
NCT04242329 2024-01-26
SUMMIST
Vastra Gotaland Region
Phase 2 Withdrawn
NCT05482074 2024-01-19
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT05299580 2023-09-14
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
Phase 2 Withdrawn
NCT05561491 2023-06-22
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
Targovax ASA
Phase 2 Withdrawn
NCT04987996 2023-06-06
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
Phase 2 Withdrawn
NCT04703426 2023-05-22
Sargramostim (GM-CSF) + PD-1
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04042506 2021-04-12
SBRT as a Vaccination for Metastatic Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT04495010 2021-03-19
CheckMate 7UA
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03758729 2021-02-16
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Samsung Medical Center
Phase 2 Withdrawn
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT02263898 2020-07-27
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01355562 2020-04-30
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
Phase 2 Withdrawn
NCT04007588 2020-02-05
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT02763761 2018-10-09
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01833767 2017-08-24
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Western Regional Medical Center
Phase 2 Withdrawn
NCT02400385 2017-02-01
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
California Pacific Medical Center Research Institute
Phase 2 Withdrawn
NCT02061007 2016-05-09
Biomarker Correlates of Hypoxia in Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn
NCT01851408 2015-04-15
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01933061 2014-02-04
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
Celgene
Phase 2 Withdrawn
NCT00357461 2013-05-15
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT01416844 2013-03-07
Study of Immune Responses in Patients With Metastatic Melanoma
Providence Health & Services
Phase 2 Withdrawn
NCT01216787 2013-01-31
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00085579 2012-12-12
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT00963664 2009-09-09
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NeoPlas Innovation
Phase 2 Withdrawn